-37.6%
SMCI vs MRNA
+945.0%
-982.6%
-56.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.7% | +13.1% | -18.8% | -6.2% |
| 7D | -17.3% | +20.6% | -38.0% | -17.9% |
| 30D | -31.5% | +27.1% | -58.6% | -32.1% |
| 3M | -6.6% | +353.4% | -360.0% | -14.5% |
| 6M | +6.0% | +446.3% | -440.2% | -14.0% |
| YTD | +1.1% | +776.2% | -775.0% | -27.7% |
| 1Y | -37.6% | +987.9% | -1,025.5% | -60.4% |
| All | -37.6% | +945.0% | -982.6% | -60.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling